1.12
-0.02(-1.75%)
Currency In USD
| Previous Close | 1.14 |
| Open | 1.14 |
| Day High | 1.15 |
| Day Low | 1.07 |
| 52-Week High | 2.74 |
| 52-Week Low | 0.36 |
| Volume | 1.77M |
| Average Volume | 5.44M |
| Market Cap | 134.34M |
| PE | -1.22 |
| EPS | -0.92 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 0.8 |
| Change | -0.02 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $53.64 as of September 29, 2025 at a share price of $1.12. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $369.64 as of September 29, 2025 at a share price of $1.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
GlobeNewswire Inc.
Sep 24, 2025 8:01 PM GMT
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
GlobeNewswire Inc.
Sep 17, 2025 11:01 AM GMT
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Inviv
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
GlobeNewswire Inc.
Sep 04, 2025 11:01 AM GMT
SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to